A phase III trial found that Lantheus Medical Imaging's flurpiridaz F-18 investigational PET radiopharmaceutical outperformed SPECT myocardial perfusion imaging (MPI) in patients with suspected coronary artery disease.
Presented at this week's American Society of Nuclear Cardiology annual meeting, the trial found that flurpiridaz F-18-PET met its primary co-endpoints, exceeding a 60% threshold for sensitivity and specificity for detecting coronary artery disease, according to Lantheus and partner GE Healthcare.
The results also showed that flurpiridaz F-18 PET yielded higher diagnostic efficacy and image quality than SPECT MPI, according to the vendors. The phase III open-label study involved over 600 patients across sites in the U.S., Europe, and Canada.
GE has led the funding and development of flurpiridaz F-18 and will hold global commercialization rights if the imaging agent is approved. Meanwhile, Lantheus has collaborated on development and will collaborate on potential commercialization through a joint steering committee, the vendors said.
